Pleomorphic adenoma surgery: Difference between revisions
| Line 45: | Line 45: | ||
*Recurrence is also noticed after surgery. | *Recurrence is also noticed after surgery. | ||
*The main causes for recurrence are:<ref name="pmid27386926">{{cite journal |vauthors=Kiciński K, Mikaszewski B, Stankiewicz C |title=Risk factors for recurrence of pleomorphic adenoma |journal=Otolaryngol Pol |volume=70 |issue=3 |pages=1–7 |date=February 2016 |pmid=27386926 |doi=10.5604/00306657.1193691 |url=}}</ref> | *The main causes for recurrence are:<ref name="pmid27386926">{{cite journal |vauthors=Kiciński K, Mikaszewski B, Stankiewicz C |title=Risk factors for recurrence of pleomorphic adenoma |journal=Otolaryngol Pol |volume=70 |issue=3 |pages=1–7 |date=February 2016 |pmid=27386926 |doi=10.5604/00306657.1193691 |url=}}</ref> | ||
** Incomplete excision | ** Incomplete excision | ||
**Intraoperative capsule rupture | **Intraoperative capsule rupture | ||
**Myxoid subtype | **Myxoid subtype | ||
**Presence of the satellite nodules and tumor extensions (pseudopodia) | **Presence of the satellite nodules and tumor extensions (pseudopodia) | ||
**Lack of the glandular tissue margin and the experience of the surgeon. | **Lack of the glandular tissue margin and the experience of the surgeon. | ||
Revision as of 14:56, 16 January 2019
|
Pleomorphic adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pleomorphic adenoma surgery On the Web |
|
American Roentgen Ray Society Images of Pleomorphic adenoma surgery |
|
Risk calculators and risk factors for Pleomorphic adenoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Surgical intervention is not recommended for the management of [disease name].
OR
Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
Surgery is the mainstay of treatment for [disease or malignancy].
Indications
- Surgical intervention is not recommended for the management of [disease name].
OR
- Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either:
- [Indication 1]
- [Indication 2]
- [Indication 3]
- The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either:
- [Indication 1]
- [Indication 2]
- [Indication 3]
Surgery
Surgery is the mainstay of treatment for pleomorphic adenoma.There are two procedures:
- Superficial parotidectomy(Patey's operation).
- Total parotidectomy, being the more frequently performed procedure due to lower incidence of recurrence. [1]
- Meticulous care shouldbe taken to preserve the facial nerve. [1]
- The tumors of the submandibular glands are treated with simple excision procedure with preservation of adjacent nerve including the mandibular branch of the trigeminal nerve, the hypoglossal nerve, and the lingual nerve.
- When the tumor arises from the minor salivary glands, a five mm margin should be obtained.
- Recurrence is also noticed after surgery.
- The main causes for recurrence are:[2]
- Incomplete excision
- Intraoperative capsule rupture
- Myxoid subtype
- Presence of the satellite nodules and tumor extensions (pseudopodia)
- Lack of the glandular tissue margin and the experience of the surgeon.
Contraindications
References
- ↑ 1.0 1.1 Kadletz, Lorenz; Grasl, Stefan; Grasl, Matthäus C.; Perisanidis, Christos; Erovic, Boban M. (2017). "Extracapsular dissection versus superficial parotidectomy in benign parotid gland tumors: The Vienna Medical School experience". Head & Neck. 39 (2): 356–360. doi:10.1002/hed.24598. ISSN 1043-3074.
- ↑ Kiciński K, Mikaszewski B, Stankiewicz C (February 2016). "Risk factors for recurrence of pleomorphic adenoma". Otolaryngol Pol. 70 (3): 1–7. doi:10.5604/00306657.1193691. PMID 27386926.